Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide When Used in Combination With Pioglitazone With or Without Metformin in Subjects With Type 2 Diabetes.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide When Used in Combination With Pioglitazone With or Without Metformin in Subjects With Type 2 Diabetes.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Albiglutide (Primary) ; Metformin; Pioglitazone
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms HARMONY 1; HARMONY-1
  • Sponsors GlaxoSmithKline; GSK
  • Most Recent Events

    • 10 Jun 2021 According to a Harmony Biopharm media release, data from this trial was presented at the 35th Annual Meeting of the Associated Professional Sleep Societies (APSS).
    • 10 Jun 2021 Results published in Harmony Biosciences Media Release
    • 14 Oct 2020 According to a Harmony Biosciences media release, U.S. Food and Drug Administration (FDA) has approved WAKIX(pitolisant) for the treatment of cataplexy in adult patients with narcolepsy.FDA approval of WAKIX for the treatment of cataplexy in adult patients with narcolepsy is based on the results from HARMONY CTP and HARMONY 1 from the clinical development program for WAKIX.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top